Silverback Therapeutics (NASDAQ:SBTX) Shares Up 3.4% - Should You Buy?

Key Points

• Silverback Therapeutics shares increased by 3.4% during mid-day trading, with the stock last recorded at $10.05 after hitting a high of $10.40.
• Trading volume surged to approximately 3.82 million shares, marking a significant rise of 1,030% compared to its average daily volume.
• The biopharmaceutical company focuses on developing tissue-targeted therapeutics for chronic viral infections and cancer, with a lead product aimed at treating chronic hepatitis B virus infection.

Silverback Therapeutics, Inc. (NASDAQ:SBTX - ) was up 3.4% during mid-day trading on Wednesday . The stock traded as high as $10.40 and last traded at $10.05. Approximately 3,819,986 shares were traded during trading, an increase of 1,030% from the average daily volume of 337,931 shares. The stock had previously closed at $9.72.

Silverback Therapeutics Stock Performance

The company's 50-day moving average is $13.36 and its 200-day moving average is $14.22. The firm has a market cap of $362.38 million, a price-to-earnings ratio of -4.15 and a beta of 0.60.

About Silverback Therapeutics

Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.